Sequenom (SQNM) rises 4% after announcing "numerous leading healthcare providers" in the U.S....


Sequenom (SQNM) rises 4% after announcing "numerous leading healthcare providers" in the U.S. have begun ordering its MaterniT21 product, which is used to analyze a baby's DNA during pregnancy for signs of Down Syndrome. Ed Pullen believes the nature of Sequenom's product "raises huge questions" about its usage. (previously)

Comments (1)
  • Director one
    , contributor
    Comments (62) | Send Message
     
    This should reduce medical costs in the long run for many families.....Who is Ed Pullen a short in the stock?
    19 Dec 2011, 08:48 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs